Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study
In brief
Tarlatamab extends median survival by 5 months over chemotherapy in small-cell lung cancer
After about 23 months of follow-up, patients whose small-cell lung cancer progressed after platinum chemotherapy lived a median 13.6 months with tarlatamab, versus 8.4 months with chemotherapy. Responses were more frequent and often lasted longer, while treatment-related side effects rarely led to stopping therapy; cytokine release syndrome and neurologic effects occurred mainly early in treatment.
- Journal
- Annals of oncology : official journal of the European Society for Medical Oncology (Q1)
- Published
- 31 December 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- C M Rudin, M-J Ahn, M Schuler, F H Blackhall, G Mountzios, T Yoshida, et al.
- PMID
- 42933636
- DOI
- 10.1016/j.annonc.2026.10.095
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (top studies of the week, 22 November 2026): Extended randomized-trial results evaluate tarlatamab for SCLC
Abstract
BACKGROUND: In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended follow-up in patients with small-cell lung cancer (SCLC). PATIENTS AND METHODS: In this phase 3, open-label trial, patients with SCLC whose disease had progressed on or after platinum-based chemotherapy were randomized (1:1) to receive either tarlatamab or chemotherapy (topotecan, lurbinectedin, or amrubicin) until disease progression, unacceptable toxicity, or death. The primary endpoint was OS. Secondary endpoints included investigator-assessed PFS, objective response, disease control, duration of response per RECIST v1.1, PROs, and safety. RESULTS: As of data cutoff (18 February 2026), median OS was 13.6 and 8.4 months with tarlatamab and chemotherapy, respectively (median follow-up, 23.3 and 22.8 months). Median PFS was 4.2 and 3.2 months, respectively (median follow-up, 22.2 and 21.9 months). Kaplan-Meier estimated OS rates at 12/24 months were 55.9%/30.3% with tarlatamab versus 39.0%/14.9% with chemotherapy; corresponding PFS rates at 12/24 months were 20.6%/14.2% versus 5.9%/2.3%. Objective response rate was 35.4% with tarlatamab, including six confirmed complete responses versus 20.4% with chemotherapy; at data cutoff, ongoing responses were observed in 31.1% (28/90) versus 3.8% (2/52) of responders, respectively. Sustained disease control for ≥52 weeks was observed in 24.4% versus 4.3%. Treatment-related adverse events led to treatment discontinuation in 3.2% versus 6.6%; grade ≥3 events decreased over time, with no serious TRAEs with onset ≥12 months. CRS and ICANS occurred early in treatment and were predominantly low grade. CONCLUSIONS: With extended follow-up, tarlatamab continues to demonstrate sustained and durable clinical benefit and a favorable long-term tolerability profile versus chemotherapy, in patients with SCLC after first-line platinum-based chemotherapy, supporting its use as the standard of care in this setting.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.